RAS mutation status and bortezomib therapy for relapsed multiple myeloma

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2141|169|6|905-908

ISSN： 0007-1048

Source： BRITISH JOURNAL OF HAEMATOLOGY, Vol.169, Iss.6, 2015-06, pp. : 905-908

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Retreatment and prolonged therapy with subcutaneous bortezomib in patients with relapsed multiple myeloma: A randomized, controlled, phase III study

By  

EUROPEAN JOURNAL OF HAEMATOLOGY, Vol. 100, Iss. 1, 2018-01 ,pp. : 10-19

John Wiley & Sons Inc

Access to resources Recommend Favorite

The addition of dexamethasone to bortezomib for patients with relapsed multiple myeloma improves outcome but ongoing maintenance therapy has minimal benefit

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 5, 2015-05 ,pp. : E86-E91

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical Value of Absolute Lymphocyte Counts before Bortezomib-Dexamethasone Therapy in Relapsed Multiple Myeloma Patients

By  

Acta Haematologica, Vol. 124, Iss. 1, 2010-07 ,pp. : 34-39

Karger

Access to resources Recommend Favorite

Combination therapy with bortezomib, continuous low‐dose cyclophosphamide and dexamethasone followed by one year of maintenance treatment for relapsed multiple myeloma patients

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 171, Iss. 5, 2015-12 ,pp. : 720-725

John Wiley & Sons Inc

Access to resources Recommend Favorite

Bortezomib in Relapsed Multiple Myeloma – Results of a Non-Interventional Study by Office-Based Haematologists

By  

Oncology Research and Treatment, Vol. 32, Iss. 4, 2009-03 ,pp. : 175-180

Karger

Access to resources Recommend Favorite